Abbott’s ARCHITECT human epididymis protein 4 (HE4) assay submitted for 510(k) clearance
ABBOTT PARK, Ill., Feb. 8 /PRNewswire-FirstCall/ — A new diagnostic tool physicians can use to monitor patients for the most common form of ovarian cancer may soon be available in the United States. Abbott’s ARCHITECT HE4 assay uses a simple blood test to help in monitoring for the recurrence or progression of epithelial ovarian cancer. If approved, this important immunoassay would be the first automated HE4 test available in the United States.
Popularity: 1% [?]
